A phase I/II study of golidocitinib, a selective JAK1 inhibitor, in refractory or relapsed peripheral T-cell lymphoma.

被引：0
|
作者：
Kim, Won Seog
Yoon, Dok Hyun
Song, Yuqin
Yang, Haiyan
Cao, Junning
Ji, Dongmei
Koh, Youngil
Jing, Hongmei
Eom, Hyeon Seok
Kwak, Jae-Yong
Lee, Won-Sik
Lee, Jong Seok
Shin, Ho-Jin
Jin, Jie
Wang, Mei
Li, Jingrun
Huang, Xubin
Deng, Xueyuan
Yang, Zhenfan
Zhu, Jun
机构：
[1] Samsung Med Ctr, Seoul, South Korea
[2] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea
[3] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China
[4] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[5] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[6] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[7] Peking Univ Third Hosp, Beijing, Peoples R China
[8] Natl Canc Ctr, Goyang, South Korea
[9] Chonbuk Natl Univ Hosp, Jeonju Si, South Korea
[10] Inje Univ, Busan Paik Hosp, Busan, South Korea
[11] Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea
[12] Pusan Natl Univ Hosp, Pusan, South Korea
[13] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Hangzhou, Peoples R China
[14] Dizal Pharmaceut, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7563
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase II study of delineukin diftitox (ONTAK®) for relapsed/refractory band T-cell non-Hodgkin's lymphoma.
    Dang, NH
    Hagemeister, FB
    Fayad, L
    Pro, B
    McLaughlin, P
    Romaguera, JE
    Samaniego, F
    Younes, A
    Goy, A
    Preti, A
    Jones, D
    Sarris, A
    East, K
    Rodriguez, MA
    Cabanillas, F
    BLOOD, 2002, 100 (11) : 363A - 363A
  • [32] Pralatrexate: Phase 1/2 Study in Japanese Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)
    Maeda, Yoshinobu
    Tobinai, Kensei
    Nagai, Hirokazu
    Nakane, Takahiko
    Shimoyama, Tatsu
    Nakazato, Tomonori
    Sakai, Rika
    Ishikawa, Takayuki
    Izutsu, Koji
    Ueda, Ryuzo
    BLOOD, 2016, 128 (22)
  • [33] Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma
    Zinzani, Pier Luigi
    Musuraca, Gerardo
    Tani, Monica
    Stefoni, Vittorio
    Marchi, Enrica
    Fina, Mariapaola
    Pellegrini, Cinzia
    Alinari, Lapo
    Derenzini, Enrico
    de Vivo, Antonio
    Sabattini, Elena
    Pileri, Stefano
    Baccarani, Michele
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (27) : 4293 - 4297
  • [34] Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma
    Kawai, Hidetsugu
    Ando, Kiyoshi
    Maruyama, Dai
    Yamamoto, Kazuhito
    Kiyohara, Eiji
    Terui, Yasuhito
    Fukuhara, Noriko
    Miyagaki, Tomomitsu
    Tokura, Yoshiki
    Sakata-Yanagimoto, Mamiko
    Igarashi, Tadahiko
    Kuroda, Junya
    Fujita, Jiro
    Uchida, Toshiki
    Ishikawa, Takayuki
    Yonekura, Kentaro
    Kato, Koji
    Nakanishi, Tadashi
    Nakai, Kenya
    Matsunaga, Risa
    Tobinai, Kensei
    CANCER SCIENCE, 2021, 112 (06) : 2426 - 2435
  • [35] Phase 2 Study of Golidocitinib, a JAK1 Selective Inhibitor, As Maintenance Therapy in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy (JACKPOT26)
    Jin, Jie
    Cai, Qingqing
    Zhang, Liling
    Zou, Liqun
    Li, Zengjun
    Wu, Huijing
    Zhou, Keshu
    Qiu, Lihua
    Su, Liping
    Ding, Kaiyang
    Zhou, Hui
    Yu, Li
    Li, Fei
    Xiao, Qing
    Li, Wenyu
    Lin, Lie
    Wang, Erhua
    Chen, Lijia
    BLOOD, 2023, 142
  • [36] Japanese subgroup analysis in the Asian phase II study of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma
    Negoro, Eiju
    Yamauchi, Takahiro
    Fukuhara, Noriko
    Yamamoto, Kazuhito
    Uchida, Toshiki
    Izutsu, Koji
    Maruyama, Dai
    Terui, Yasuhito
    Nakajima, Hideaki
    Ando, Kiyoshi
    Suehiro, Youko
    Choi, Ilseung
    Kanemura, Nobuhiro
    Nakamura, Nobuhiko
    Yamamoto, Go
    Maeda, Yoshinobu
    Shibayama, Hirohiko
    Nagahama, Fumiko
    Sonehara, Yusuke
    Nagai, Hirokazu
    Tien, Hwei-Fang
    Kwong, Yok-Lam
    Kim, Won-Seog
    Tobinai, Kensei
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2023, 63 (02) : 108 - 120
  • [37] A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma
    Strati, Paolo
    Chihara, Dai
    Oki, Yasuhiro
    Fayad, Luis E.
    Fowler, Nathan
    Nastoupil, Loretta
    Romaguera, Jorge E.
    Samaniego, Felipe
    Garg, Naveen
    Feng, Lei
    Wesson, Emily T.
    Ruben, Charnelle E.
    Stafford, Mildred D.
    Nieto, Yago
    Khouri, Issa F.
    Hosing, Chitra
    Horowitz, Sandra B.
    T-Kamble, Rammurti
    Fanale, Michelle A.
    HAEMATOLOGICA, 2018, 103 (09) : E416 - E418
  • [38] E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma: A phase I study
    Ohmachi, Ken
    Ando, Kiyoshi
    Ogura, Michinori
    Uchida, Toshiki
    Tobinai, Kensei
    Maruyama, Dai
    Namiki, Masayuki
    Nakanishi, Tadashi
    CANCER SCIENCE, 2018, 109 (03): : 794 - 802
  • [39] Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma
    Phillips, Tycel J.
    Forero-Torres, Andres
    Sher, Taimur
    Diefenbach, Catherine S.
    Johnston, Patrick
    Talpaz, Moshe
    Pulini, Jennifer
    Zhou, Li
    Scherle, Peggy
    Chen, Xuejun
    Barr, Paul M.
    BLOOD, 2018, 132 (03) : 293 - 306
  • [40] Phase II study of chidamide (CS055), a new subtype-selective oral histone deacetylase inhibitor, in patients with relapsed or refractory peripheral T-cell lymphoma
    Shi, Yuan-Kai
    Dong, Mei
    Hong, Xiao-Nan
    Zhang, Wei-Jing
    Feng, Ji-Feng
    Zhu, Jun
    Yu, Li
    Ke, Xiao-Yan
    Huang, Hui-Qiang
    Shen, Zhi-Xiang
    Fan, Yun
    Li, Wei
    Zhao, Xie-Lan
    Qiu, Lu-Gui
    Huang, He
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345